皮奥格利塔 PPARγ 激动剂 通过重编程葡萄糖代谢来预防缺氧引起的心脏功能障碍
Yijin Wang1, Ru Zhang2, Qian Chen1
1College of Life Sciences, Northwest University, Xi'an, 710069, China.
International journal of biological sciences
|September 9, 2024
概括
皮奥格利塔通过改善心脏新陈代谢来预防高海拔心脏问题,独立于胰岛素的影响. 这种药物增强了心脏细胞的功能,并通过增加葡萄糖的使用和减少氧化压力,保护心脏细胞免受低氧引起的损伤.
科学领域:
- 心血管生理学心血管生理学
- 代谢调节 代谢调节 代谢调节
- 高度医学 高度医学
背景情况:
- 高海拔低氧会对心脏结构和功能构成风险.
- 代谢可塑性是心脏的一个关键防御机制.
- 皮奥格利塔 (一种PPARγ激动剂) 影响胰岛素敏感性和葡萄糖代谢.
研究的目的:
- 调查皮奥格利塔对高海拔低氧引起的心脏功能障碍的预防作用.
- 阐明皮奥格利塔对缺氧的保护作用的机制.
主要方法:
- 使用了一种小鼠模型,暴露于高海拔低氧4周.
- 在初级心肌细胞上进行了体外实验.
- 评估心脏功能,收缩性,QT间隔和代谢参数.
- 研究过氧酶增殖器激活受体γ (PPARγ) 和缺氧诱导因子1α (HIF-1α) 的作用.
主要成果:
- 皮奥格利塔在缺氧小鼠中预防了心脏功能障碍,独立于胰岛素敏感性.
- 在体外,皮奥格利塔增强了心肌细胞收缩性,并在低氧条件下减少了QT间隔延长.
- 皮奥格利塔促进了心脏葡萄糖的代谢重编程,增加了糖分分解能力和葡萄糖氧化.
- 它减少了线粒体的活性氧物种 (ROS) 生产,保持了膜潜力和ATP水平.
- 皮奥格利塔在缺氧心肌中增加了缺氧诱导因子1α (HIF-1α) 的表达.
- 抑制HIF-1α抑制了皮奥格利塔的代谢重编程和保护作用.
结论:
- 皮奥格利塔有效地预防高海拔低氧引起的心脏功能障碍.
- 保护机制涉及通过PPARγ依赖的途径重编程心脏葡萄糖代谢,涉及HIF-1α.
- 皮奥格利塔为管理高海拔地区心脏问题提供了潜在的治疗策略.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Cell Specific Gene Expression
13.5K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.5K
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216


